ASTRAZENECA PLC reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge
SEC filing record 1 source field available
Fiscal year end
31 December
ASTRAZENECA PLC has filed 2,050 SEC EDGAR filings since 13 Mar 1995

SEC filing history

Showing 451-475 of 1,000 matching filings.

Per page
25
Current page
19
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
03 Jan 2023
Reporting date
03 Jan 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
30 Dec 2022
Reporting date
30 Dec 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

CALQUENCE JAPAN APPROVAL FOR TREATMENT-NAIVE CLL

Filing date
28 Dec 2022
Reporting date
28 Dec 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI, IMJUDO APPROVED IN JAPAN FOR 3 CANCERS

Filing date
28 Dec 2022
Reporting date
28 Dec 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI APPROVED IN EU FOR BILIARY TRACT CANCER

Filing date
21 Dec 2022
Reporting date
21 Dec 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA APPROVED IN EU FOR PROSTATE CANCER

Filing date
21 Dec 2022
Reporting date
21 Dec 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR PATIENTS WITH HER2-LOW ME

Filing date
19 Dec 2022
Reporting date
19 Dec 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU APPROVED IN THE EU FOR PATIENTS WITH PREVIOUSLY TREATED HER2-POSITIVE AD

Filing date
19 Dec 2022
Reporting date
19 Dec 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI PLUS IMJUDO RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR THE TREATMENT

Filing date
19 Dec 2022
Reporting date
19 Dec 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

UPDATE ON PEARL PHASE III TRIAL OF IMFINZI MONOTHERAPY IN STAGE IV NON-SMALL CEL

Filing date
19 Dec 2022
Reporting date
19 Dec 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FORXIGA CHMP OPINION FOR SYMPTOMATIC CHRONIC HF

Filing date
19 Dec 2022
Reporting date
19 Dec 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

UPDATE ON US REVIEW OF LYNPARZA PROPEL SNDA

Filing date
15 Dec 2022
Reporting date
15 Dec 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

CAPIVASERTIB PFS IN HR-POSITIVE BREAST CANCER

Filing date
08 Dec 2022
Reporting date
08 Dec 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Dec 2022
Reporting date
01 Dec 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

BLOCK LISTING INTERIM REVIEW

Filing date
01 Dec 2022
Reporting date
01 Dec 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA ANNOUNCES SALE OF WEST CHESTER SITE

Filing date
30 Nov 2022
Reporting date
30 Nov 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA TO ACQUIRE NEOGENE THERAPEUTICS

Filing date
29 Nov 2022
Reporting date
29 Nov 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
23 Nov 2022
Reporting date
23 Nov 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU RECOMMENDED FOR EU APPROVAL IN GASTRIC

Filing date
14 Nov 2022
Reporting date
14 Nov 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI RECOMMENDED FOR APPROVAL IN THE EU FOR BTC

Filing date
14 Nov 2022
Reporting date
14 Nov 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA COMBO RECOMMENDED IN THE EU FOR MCRPC

Filing date
14 Nov 2022
Reporting date
14 Nov 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI + IMJUDO APPROVED IN US FOR LUNG CANCER

Filing date
14 Nov 2022
Reporting date
11 Nov 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

YTD AND Q3 2022 RESULTS

Filing date
10 Nov 2022
Reporting date
10 Nov 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FDA ADVISORY COMMITTEE RECOMMENDS PT027 IN ASTHMA

Filing date
09 Nov 2022
Reporting date
09 Nov 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

BEYFORTUS (NIRSEVIMAB) APPROVED IN EU

Filing date
04 Nov 2022
Reporting date
04 Nov 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .